We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immune Cells Adapt Inefficiently in Patients with Uncontrolled HIV

By LabMedica International staff writers
Posted on 28 Mar 2016
Antibodies derived from a type of immune cell found in unusually high numbers in human immunodeficiency virus (HIV)-infected individuals with chronically uncontrolled virus levels are less effective at neutralizing HIV than antibodies derived from a different type of immune cell more common in people without HIV.

HIV infection leads to numerous immunologic abnormalities, especially in individuals whose viremia is not well controlled, either naturally or by antiretroviral therapy (ART). More...
B cells are not direct targets for HIV replication; however, direct and indirect consequences of viral replication such as immune activation and lymphopenia lead to numerous B cell abnormalities over the course of infection.

Scientists at the US National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) and their colleagues collected serum and/or leukapheresis products from 25 chronically infected HIV-viremic individuals. The donors were not taking antiretroviral drugs to suppress the level of HIV in their blood, or viral load, at the time of the study. Like many individuals with persistent levels of HIV, the donors' blood samples had abnormally high numbers of immune cells called tissue-like memory (TLM) B cells, compared with resting memory (RM) B cells, which account for the majority of memory B cells in people without HIV.

Peripheral blood mononuclear cells (PBMCs) were obtained by density-gradient centrifugation. Mature CD10-B cells were isolated from PBMCs by negative magnetic bead–based selection using a B cell enrichment cocktail that was supplemented with tetrameric anti-CD10 monoclonal antibodies (mAb) (STEMCELL Technologies; Vancouver, BC, Canada). Immunophenotyping to identify suitable subjects for sorting was performed using the following anti-human mAbs. Fluorescent activated cell sorting (FACS) analyses were performed on a FACSCanto II flow cytometer and sorting of B cell populations and of single HIV-specific B cells into 96-well polymerase chain reaction (PCR) plates was performed on a modified 3-laser FACSAria instrument (BD Biosciences; San Jose, CA, USA).

Generally, as B cells divide in response to a pathogen like HIV, genes that produce infection-fighting antibodies mutate, and descendant cells producing the most effective antibodies predominate. Despite the fact that TLM B cells generally divided more frequently than their RM counterparts, the scientists found that the antibodies derived from TLM B cells showed genetic evidence of fewer adaptive mutations than those derived from RM B cells. In turn, these antibodies were less likely to effectively neutralize HIV than those derived from RM B cells. The RM B cells, in contrast, showed evidence of generating antibodies with more helpful mutations.

The authors concluded that nonconventional TLM B cells overrepresented in the peripheral blood of chronically infected HIV-viremic individuals show reduced affinity maturation compared with their clonally related conventional RM counterparts, despite evidence of having undergone more cell divisions. The study was published on March 17, 2016, in the journal JCI Insight.

Related Links:

US National Institute of Allergy and Infectious Diseases 
STEMCELL Technologies 
BD Biosciences 



New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.